SELLAS Life Sciences Group (NASDAQ:SLS) Posts Earnings Results, Beats Estimates By $0.03 EPS

SELLAS Life Sciences Group (NASDAQ:SLS) announced its earnings results on Thursday. The company reported ($0.08) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.03, Zacks reports. During the same period in the prior year, the business posted ($1.34) EPS.

SELLAS Life Sciences Group Price Performance

Shares of NASDAQ:SLS opened at $1.20 on Friday. The company has a market capitalization of $84.46 million, a P/E ratio of -1.74 and a beta of 2.43. SELLAS Life Sciences Group has a 1 year low of $0.77 and a 1 year high of $1.84. The business’s 50 day simple moving average is $1.21 and its 200 day simple moving average is $1.17.

SELLAS Life Sciences Group Company Profile

SELLAS Life Sciences Group, Inc, a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company’s lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.